Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the "fitness criteria" for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL).
Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Vià M, Ciceri F, Passamonti F, Mancini V, Sciumè M, Cerqui E, Sciumè M, Rossi G. Borlenghi E, et al. Among authors: da via m. J Geriatr Oncol. 2021 May;12(4):550-556. doi: 10.1016/j.jgo.2020.10.004. Epub 2020 Oct 20. J Geriatr Oncol. 2021. PMID: 33097455
Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).
Cattaneo C, Zappasodi P, Mancini V, Annaloro C, Pavesi F, Skert C, Ferrario A, Todisco E, Saccà V, Verga L, Passi A, Da Vià M, Ferrari S, Mometto G, Petullà M, Nosari A, Rossi G. Cattaneo C, et al. Among authors: da via m. Ann Hematol. 2016 Dec;95(12):1955-1963. doi: 10.1007/s00277-016-2815-7. Epub 2016 Sep 21. Ann Hematol. 2016. PMID: 27650830
Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).
Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Todisco E, Fracchiolla N, Mancini V, Turrini M, Da Vià M, Sala E, Cattaneo C, Petullà M, Serana F, Ferrario A, Cairoli R, Cortelezzi A, Santoro A, Castagnola C, Rossi G. Borlenghi E, et al. Among authors: da via m. Am J Hematol. 2018 Feb;93(2):E54-E57. doi: 10.1002/ajh.24977. Epub 2017 Dec 4. Am J Hematol. 2018. PMID: 29164738 Free article. No abstract available.
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P, Marbello L, Borlenghi E, Fumagalli M, Bernardi M, Fracchiolla N, Mancini V, Da Vià M, Ravano E, Cerqui E, Ferretti VV, Rocca B, Calvello C, Cazzola M, Castagnola C, Rossi G. Zappasodi P, et al. Among authors: da via m. Ann Hematol. 2018 Nov;97(11):2107-2115. doi: 10.1007/s00277-018-3424-4. Epub 2018 Jul 15. Ann Hematol. 2018. PMID: 30009341 Clinical Trial.
Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients.
Fattizzo B, Bortolotti M, Rampi N, Cavallaro F, Giannotta JA, Bucelli C, Cassin R, Da Vià MC, Galassi G, Noto A, Pettine L, Rossi FG, Sciumè M, Ceriotti F, Consonni D, Barcellini W, Baldini L. Fattizzo B, et al. Among authors: da via mc. Front Immunol. 2022 May 12;13:852158. doi: 10.3389/fimmu.2022.852158. eCollection 2022. Front Immunol. 2022. PMID: 35634287 Free PMC article.
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, Gallì A, Da Vià MC, Conte S, Tauro S, Keenan N, Hyslop A, Hinton J, Mudie LJ, Wainscoat JS, Futreal PA, Stratton MR, Campbell PJ, Hellström-Lindberg E, Cazzola M; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Malcovati L, et al. Among authors: da via mc. Blood. 2011 Dec 8;118(24):6239-46. doi: 10.1182/blood-2011-09-377275. Epub 2011 Oct 12. Blood. 2011. PMID: 21998214 Free PMC article.
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Gallì A, Della Porta MG, Travaglino E, Pietra D, Pascutto C, Ubezio M, Bono E, Da Vià MC, Brisci A, Bruno F, Cremonesi L, Ferrari M, Boveri E, Invernizzi R, Campbell PJ, Cazzola M. Malcovati L, et al. Among authors: da via mc. Blood. 2014 Aug 28;124(9):1513-21. doi: 10.1182/blood-2014-03-560227. Epub 2014 Jun 26. Blood. 2014. PMID: 24970933 Free PMC article.
Editorial: Immunologic Mechanisms of Myeloid Neoplasms.
Fattizzo B, Da Vià MC, Kulasekararaj AG. Fattizzo B, et al. Among authors: da via mc. Front Oncol. 2022 Jun 15;12:949633. doi: 10.3389/fonc.2022.949633. eCollection 2022. Front Oncol. 2022. PMID: 35785196 Free PMC article. No abstract available.
Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept.
Fattizzo B, Marchetti A, Zaninoni A, Lionetti M, Riva M, Rizzo L, Pettine L, Galli N, Mazzon F, Fermo E, Maeda A, Marella A, Da Vià MC, Passamonti F, Bolli N, Barcellini W. Fattizzo B, et al. Among authors: da via mc. Am J Hematol. 2023 Nov;98(11):E345-E348. doi: 10.1002/ajh.27072. Epub 2023 Sep 12. Am J Hematol. 2023. PMID: 37698348 No abstract available.
44 results